Prognostic impact of serum transthyretin in patients with non‑small cell lung cancer

Shimura,Tatsuo; Shibata,Masahiko; Inoue,Takuya; Owada‑Ozaki,Yuki; Yamaura,Takumi; Muto,Satoshi; Hasegawa,Takeo; Shio,Yutaka; Suzuki,Hiroyuki

doi:10.3892/mco.2019.1837

Prognostic impact of serum transthyretin in patients with non‑small cell lung cancer

Authors:
- Tatsuo Shimura
- Masahiko Shibata
- Takuya Inoue
- Yuki Owada‑Ozaki
- Takumi Yamaura
- Satoshi Muto
- Takeo Hasegawa
- Yutaka Shio
- Hiroyuki Suzuki
View Affiliations

Affiliations: Department of Progressive DOHaD Research, Fukushima Medical University, Fukushima 960‑1295, Japan, Department of Advanced Cancer Immunotherapy, Fukushima Medical University, Fukushima 960‑1295, Japan, Department of Chest Surgery, Fukushima Medical University, Fukushima 960‑1295, Japan
Published online on: April 3, 2019 https://doi.org/10.3892/mco.2019.1837
Pages: 597-604

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The identification of novel biomarkers is of great importance for improving the outcome of patients with non‑small cell lung cancer (NSCLC). Therefore, the aim of the present study was to determine whether the serum transthyretin (TTR) level could be used as a novel prognostic biomarker for patients with NSCLC. Serum TTR levels, and nutritional and inflammatory parameters were examined prior to treatment in 42 patients with NSCLC. Candidates for independent predictors of prognostic factors were subjected to univariate and multivariate analyses using a Cox proportional hazard model. IL‑12‑productivity, serum retinol binding protein, albumin and transferrin levels, and lymphocyte‑to‑monocyte ratio were significantly lower in the patients with TTR <22 mg/dl than those in the patients with TTR ≥22 mg/dl. Patients with serum TTR levels of <22 mg/dl exhibited a poorer overall (P=0.008) and recurrence‑free survival (P=0.027) when compared with those with serum TTR levels of ≥22 mg/dl. The parameters, ≥T2 and age ≥75 years were independent prognostic factors for overall survival, and TTR <22 mg/dl and ≥T2 were independent prognostic factors for recurrence‑free survival. In conclusion, anthropometric measurement of serum TTR, as well as T category, can be useful for predicting the 5‑year recurrence‑free survival of patients with NSCLC.

View Figures

View References

1	Yoon HI, Kwon OR, Kang KN, Shin YS, Shin HS, Yeon EH, Kwon KY, Hwang I, Jeon YK, Kim Y and Kim CW: Diagnostic value of combining tumor and inflammatory markers in lung cancer. J Cancer Prev. 21:187–193. 2016. View Article : Google Scholar : PubMed/NCBI
2	Herbst RS, Heymach JV and Lippman SM: Lung cancer. N Engl J Med. 359:1367–1380. 2008. View Article : Google Scholar : PubMed/NCBI
3	McMillan DC: The systemic inflammation-based Glasgow prognostic score: A decade of experience in patients with cancer. Cancer Treat Rev. 39:534–540. 2013. View Article : Google Scholar : PubMed/NCBI
4	Osugi J, Muto S, Matsumura Y, Higuchi M, Suzuki H and Gotoh M: Prognostic impact of the high-sensitivity modified Glasgow prognostic score in patients with resectable non-small cell lung cancer. J Cancer Res Ther. 12:945–951. 2016. View Article : Google Scholar : PubMed/NCBI
5	Spiekerman AM: Nutritional assessment (protein nutriture). Anal Chem. 67:429R–436R. 1995. View Article : Google Scholar : PubMed/NCBI
6	Caccialanza R, Palladini G, Klersy C, Cena H, Vagia C, Cameletti B, Russo P, Lavatelli F and Merlini G: Nutritional status of outpatients with systemic immunoglobulin light-chain amyloidosis 1. Am J Clin Nutr. 83:350–354. 2006. View Article : Google Scholar : PubMed/NCBI
7	Rambod M, Kovesdy CP, Bross R, Kopple JD and Kalantar-Zadeh K: Association of serum prealbumin and its changes over time with clinical outcomes and survival in patients receiving hemodialysis. Am J Clin Nutr. 88:1485–1494. 2008. View Article : Google Scholar : PubMed/NCBI
8	Devakonda A, George L, Raoof S, Esan A, Saleh A and Bernstein LH: Transthyretin as a marker to predict outcome in critically ill patients. Clin Biochem. 41:1126–1130. 2008. View Article : Google Scholar : PubMed/NCBI
9	Ding H, Liu J, Xue R, Zhao P, Qin Y, Zheng F and Sun X: Transthyretin as a potential biomarker for the differential diagnosis between lung cancer and lung infection. Biomed Rep. 2:765–769. 2014. View Article : Google Scholar : PubMed/NCBI
10	Hao S, Sun S, Xiao X, He D and Liu L: Selective expression of transthyretin in subtypes of lung cancer. J Mol Histol. 47:239–247. 2016. View Article : Google Scholar : PubMed/NCBI
11	Kawai H and Ota H: Low perioperative serum prealbumin predicts early recurrence after curative pulmonary resection for non-small-cell lung cancer. World J Surg. 36:2853–2857. 2012. View Article : Google Scholar : PubMed/NCBI
12	Alifano M, Mansuet-Lupo A, Lococo F, Roche N, Bobbio A, Canny E, Schussler O, Dermine H, Régnard JF, Burroni B, et al: Systemic inflammation, nutritional status and tumor immune microenvironment determine outcome of resected non-small cell lung cancer. PLoS One. 9:e1069142014. View Article : Google Scholar : PubMed/NCBI
13	Asamura H: Lung, pleural, and thymic tumors. In: TNM Classification of Malignant Tumours. (8th edition. Brierley JD, Gospodarowicz MK and Wittekind C (ed.) John Wiley & Sons, Ltd., West Sussex). 105–118. 2017.
14	Sun X, Dyson HJ and Wright PE: Fluorotryptophan incorporation modulates the structure and stability of transthyretin in a site-specific manner. Biochemistry. 56:5570–5581. 2017. View Article : Google Scholar : PubMed/NCBI
15	Kelly P, Paulin F, Lamont D, Baker L, Clearly S, Exon D and Thompson A: Pre-treatment plasma proteomic markers associated with survival in oesophageal cancer. Br J Cancer. 106:955–961. 2012. View Article : Google Scholar : PubMed/NCBI
16	Han WX, Chen ZM, Wei ZJ and Xu AM: Preoperative pre-albumin predicts prognosis of patients after gastrectomy for adenocarcinoma of esophagogastric junction. World J Surg Oncol. 14:2792016. View Article : Google Scholar : PubMed/NCBI
17	Fujii T, Sutoh T, Morita H, Katoh T, Yajima R, Tsutsumi S, Asao T and Kuwano H: Serum albumin is superior to prealbumin for predicting short-term recurrence in patients with operable colorectal cancer. Nutr Cancer. 64:1169–1173. 2012. View Article : Google Scholar : PubMed/NCBI
18	Chen J, Chen LJ, Xia YL, Zhou HC, Yang RB, Wu W, Lu Y, Hu LW and Zhao Y: Identification and verification of transthyretin as a potential biomarker for pancreatic ductal adenocarcinoma. J Cancer Res Clin Oncol. 139:1117–1127. 2013. View Article : Google Scholar : PubMed/NCBI
19	Cai W, Kong W, Dong B, Zhang J, Chen Y, Xue W, Huang Y, Zhou L and Huang J: Pretreatment serum prealbumin as an independent prognostic indicator in patients with metastatic renal cell carcinoma using tyrosine kinase inhibitors as first-line target therapy. Clin Genitourin Cancer. 15:e437–e446. 2017. View Article : Google Scholar : PubMed/NCBI
20	Smyth MJ, Taniguchi M and Street SE: The anti-tumor activity of IL-12: Mechanisms of innate immunity that are model and dose dependent. J Immunol. 165:2665–2670. 2000. View Article : Google Scholar : PubMed/NCBI
21	Hu P, Shen H, Wang G, Zhang P, Liu Q and Du J: Prognostic significance of systemic inflammation-based lymphocyte-monocyte ratio in patients with lung cancer: Based on a large cohort study. PLoS One. 9:e1080622014. View Article : Google Scholar : PubMed/NCBI
22	Porrata LF, Ristow K, Colgan JP, Habermann TM, Witzig TE, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Nowakowski GS, et al: Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin's lymphoma. Haematologica. 97:262–269. 2012. View Article : Google Scholar : PubMed/NCBI
23	Nishijima TF, Muss HB, Shachar SS, Tamura K and Takamatsu Y: Prognostic value of lymphocyte-to-monocyte ratio in patients with solid tumors: A systematic review and meta-analysis. Cancer Treat Rev. 41:971–978. 2015. View Article : Google Scholar : PubMed/NCBI